Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.12 | — | — | — | — | — | — | 18.19 | — | — | — | — | 21.98 | — | — | — | — | 427.63 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 17.02 | 129.20 | 9.49 | 44.40 | 40.35 | 30.63 | 35.78 | 6.36 | — | 8.21 | 15.90 | 4.76 | 3.12 | 4.34 | 8.54 | 132.76 | 297.35 | 144.04 | 17.29 | 25.44 | 1.71 |
| — | +321.8% | -73.5% | +597.9% | — | +273.3% | +125.0% | +33.6% | — | +89.0% | +86.1% | -96.4% | -98.9% | -97.0% | -50.6% | +421.9% | +17334.8% | +380.6% | — | +150.2% | -92.8% | |
| P/B Ratio | 1.21 | 2.59 | 2.84 | 5.82 | 9.86 | 7.65 | 7.64 | 10.17 | 7.27 | 146.99 | 31.42 | 13.97 | — | — | — | — | 101.04 | 6.98 | 15.48 | 5.53 | 8.31 |
| — | -66.2% | -62.9% | -42.8% | +35.6% | -94.8% | -75.7% | -27.2% | — | — | — | — | — | — | — | — | +1115.9% | -54.2% | +196.8% | +30.5% | +176.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.30 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | 18.45 | — | — | — | — | 22.55 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | 15.85 | — | — | — | — | 28.62 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.3% | 100.0% | 100.0% | 86.9% | 100.0% | 74.8% | 76.4% | 100.0% | 100.0% | 100.0% | 100.0% | 92.5% | 35.7% | -50.7% | -139.6% | -2408.3% | -9575.4% | -7828.8% | -1469.7% | -1359.5% | 14.7% |
| — | +33.8% | +30.9% | -13.1% | 0.0% | -25.2% | -23.6% | +8.1% | +180.1% | +297.2% | +171.6% | +103.8% | +100.4% | +99.4% | +90.5% | -77.1% | -65448.9% | -653.1% | — | -523.1% | +102.0% | |
| Operating Margin | -504.1% | -3248.3% | -81.8% | -327.4% | -740.7% | -606.5% | -542.8% | 27.4% | 832.7% | -177.7% | -274.8% | -64.3% | 9.0% | -106.2% | -234.2% | -3516.0% | -13648.8% | -11243.7% | -2176.8% | -2045.9% | -20.9% |
| — | -435.6% | +84.9% | -1294.0% | -189.0% | -241.3% | -97.5% | +142.7% | +9121.0% | -67.4% | -17.3% | +98.2% | +100.1% | +99.1% | +89.2% | -71.9% | -65251.4% | -683.7% | — | -537.1% | +97.9% | |
| Net Margin | -478.3% | -3052.6% | -68.2% | -308.4% | -707.8% | -580.2% | -510.9% | 34.9% | 804.8% | -167.2% | -251.7% | -55.9% | 14.7% | -95.5% | -212.0% | -3527.8% | -13685.6% | -11012.3% | -2160.8% | -1970.8% | -17.1% |
| — | -426.2% | +86.7% | -982.8% | -187.9% | -247.0% | -103.0% | +162.4% | +5361.9% | -75.1% | -18.7% | +98.4% | +100.1% | +99.1% | +90.2% | -79.0% | -79911.3% | -688.6% | — | -546.2% | +98.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.6% | -14.4% | -5.0% | -16.3% | -40.8% | -32.4% | -24.6% | 16.3% | -80.3% | -221.1% | -97.1% | -41.0% | — | — | — | — | -227.4% | -213.0% | -187.6% | -111.5% | -24.1% |
| — | +55.7% | +79.6% | -200.3% | +49.1% | +85.3% | +74.7% | +139.7% | — | — | — | — | — | — | — | — | -844.4% | -105.2% | -216.9% | -285.1% | +59.4% | |
| ROA | -41.3% | -12.1% | -4.3% | -12.1% | -21.8% | -18.7% | -14.6% | 8.2% | -21.8% | -14.8% | -12.4% | -6.8% | 3.4% | -8.5% | -13.3% | -26.7% | -19.8% | -21.7% | -20.2% | -17.1% | -3.1% |
| — | +35.3% | +70.8% | -246.8% | -0.2% | -25.9% | -18.3% | +220.2% | -745.5% | -74.7% | +6.6% | +74.3% | +117.1% | +60.9% | +34.4% | -56.2% | -545.2% | -25.7% | -24.1% | -74.7% | +76.2% | |
| ROIC | — | -98.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.10 | 0.03 | 0.03 | 0.16 | 0.16 | 0.14 | 0.12 | 0.18 | 6.57 | 1.20 | 0.81 | — | — | — | — | 11.50 | 1.28 | 3.67 | 0.92 | 0.89 |
| — | -38.3% | -77.6% | -72.2% | -12.6% | -97.6% | -88.6% | -85.0% | — | — | — | — | — | — | — | — | +1194.4% | +1.4% | +582.8% | +184.8% | +218.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | 1.01 | — | — | — | — | 5.97 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.47 | 7.13 | 11.26 | 6.47 | 2.51 | 2.56 | 2.95 | 2.89 | 1.90 | 0.99 | 1.19 | 1.26 | 1.59 | 1.32 | 1.66 | 1.38 | 2.05 | 2.50 | 2.13 | 2.53 | 4.99 |
| — | +178.8% | +281.5% | +124.0% | +32.0% | +157.3% | +148.9% | +128.7% | +19.8% | -24.5% | -28.4% | -8.4% | -22.5% | -47.3% | -22.1% | -45.6% | -59.0% | -26.8% | -46.8% | +33.2% | +111.9% | |
| Quick Ratio | 6.47 | 7.13 | 11.26 | 6.47 | 2.51 | 2.56 | 2.95 | 2.89 | 1.90 | 0.99 | 1.19 | 1.26 | 1.59 | 1.32 | 1.66 | 1.38 | 2.05 | 2.50 | 2.13 | 2.53 | 4.99 |
| — | +178.8% | +281.5% | +124.0% | +32.0% | +157.3% | +148.9% | +128.7% | +19.8% | -24.5% | -28.4% | -8.4% | -22.5% | -47.3% | -22.1% | -45.6% | -59.0% | -26.8% | -46.8% | +33.2% | +111.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -370.47 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WVE stock.
Wave Life Sciences Ltd.'s current P/E is -3.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Wave Life Sciences Ltd.'s current operating margin is -504.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Wave Life Sciences Ltd.'s business trajectory between earnings reports.